tirzepatide lactation safety Shed Is Tirzepatide Safe While Breastfeeding?

Incretin mimetic therapies, including glucagon-like peptide 1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, have substantially improved outcomes for patients, including significant weight loss and reduced risk of adverse cardiovascular events 2,3

Compounding encourages medication safety and adherence

Headaches occur in about 10% to 15% of users, most commonly during the first two weeks

It's a consequence of rapid weight loss in a calorie deficit

Endocrinology, Diabetes & Metabolism Case Reports , 2023(3), Article 23-0017

At first glance, it sounds like a contradiction